BACKGROUND Renal function declines according to age and vascular risk factors, whereas few data are available regarding genetically-mediated effects of anti-hypertensives over renal function. OBJECTIVE To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhib...

For numerous years, the non-cardiovascular role of the renin-angiotensin system (RAS) was underestimated, but recent studies have advanced the understanding of its function in various processes, including carcinogenesis. Numerous evidence comes from preclinical and clinical studies on the use of antihypertensive agents targeting the RAS, including angiotensin-converting enzyme inhibitors (ACEIs...

Angiotensin II receptor blockers (ARBs) directly inhibit the angiotensin II type 1 receptors, which suppresses the renin-angiotensin-aldosterone system (RAAS). Six ARBs are approved in Canada for the treatment of hypertension, none are yet approved for the treatment of heart failure (HF). Evidence comparing ARBs to angiotensin converting enzyme inhibitors (ACEIs) in HF is still limited. A recen...

BACKGROUND Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered to have similar renoprotective effects; so far there has been no consensus about their priorities. This study aimed to compare ACEIs and ARBs for major renal outcomes and survival in a 15-year cohort of adults with diabetes. METHODS This study utilized Taiwan's medical and ph...

OBJECTIVE—This study aimed to verify whether the decreased vascular endothelial growth factor (VEGF)–to–pigment epithelium– derived factor (PEDF) ratio can serve as an indicator for the protective effect of angiotensin-converting enzyme inhibitors (ACEIs) on diabetic retinopathy (DR) and to investigate the role of mitochondrial reactive oxygen species (ROS) in the downregulated VEGF-to-PEDF ratio.

BACKGROUND Tubulointerstitial fibrosis (TIF) is a marker of progression of diabetic and non-diabetic nephropathy, correlating with creatinine clearance (CCr), and functional outcome. Angiotensin-converting-enzyme inhibitors (ACEIs) slow the rate of decline of renal function in proteinuric patients. AIM To examine whether ACEIs affect TIF, directly or indirectly. DESIGN Prospective 3-year fo...

background: beta-thalassemia major is a severe and lethal hemolytic anemia. regular transfusion is necessary for avoidance of its complications but it may end to cardiac involvement secondary to iron overload. angiotensin converting enzyme inhibitors (aceis) are useful medications even in early stages of heart failure. we studied the effects of two common aceis on improvement of heart function ...

To the Editor: Our recent study [1] has added more convincing evidence for renoprotection of angiotensinconverting enzyme inhibitors (ACEIs) by asking whether the use of ACEIs may explain our previously disclosed important findings [i.e., regional variations in incidence of end-stage renal disease (ESRD)] in Japan [2]. In this study, we used the amounts of expense spent on ACEIs as an explanati...

C1 esterase inhibitor (Berinert®) is generally used to treat severe attack of hereditary angioedema. We describe here the case of a patient who presented with a severe angioedema induced by angiotensin-converting enzyme inhibitors (ACEIs) endangering her life. It could be successfully treated with that medicine.

Bottom line In HF, higher-dose angiotensin-converting enzyme inhibitors (ACEIs), b-blockers (BBs), and angiotensin receptor blockers (ARBs) result in non-significant improvements in mortality, inconsistent decreases in HF hospitalizations, and more dizziness or hypotension (4% to 15%), dose reductions (20%), and stopping medication (2% to 8%). Starting patients on low doses and focusing on tole...